Castle Creek Biosciences

Dedicated to making life better for people living with underserved disorders with high unmet medical needs

"Castle Creek Biosciences is a world class cell and gene therapy company that is working to transform the lives of patients and the future of medicine."

— **John Maslowski,**
Chief Executive Officer

Castle Creek Biosciences, Inc., a privately-held, clinical-stage cell and gene therapy company, is leveraging its proprietary fibroblast technology platform to develop and commercialize innovative personalized therapies for underserved disorders with high unmet medical needs. Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Novel Scientific Platform

There are too many newborns, young children, growing adolescents and others living with painful, debilitating underserved disorders with few or no treatment options. This poses an enormous challenge to patients and their families, but personalized cell and gene therapies hold great promise to change their lives and rewrite the future.

Castle Creek Biosciences is leading the development of innovative personalized therapies based on its proprietary autologous fibroblast technology platform and manufacturing infrastructure to make safe and effective localized treatments that are compatible with the unique biology of each patient and have the potential to address the underlying cause of disease.

Clinical Development Pipeline

Castle Creek Biosciences is advancing clinical development programs for underserved disorders with high unmet medical needs, including epidermolysis bullosa (EB) and moderate to severe localized scleroderma.



Patients living with EB have defective genes that result in very fragile skin that is prone to blistering and wounds from any kind of friction or irritation. Symptoms can appear at birth or shortly after and persist throughout life. There is no treatment approved by the U.S. Food & Drug Administration (FDA) for EB.

Localized scleroderma is a chronic autoimmune skin disorder that leads to the excess production of collagen and causes thickening of the skin and connective tissue. In moderate to severe forms of the disorder, patients can experience discomfort, tightness and pain that limits their ability to function. There are no FDA approved therapies for this disorder.

Located outside of Philadelphia, Castle Creek Biosciences' headquarters features ~13,000 square feet of cGMP manufacturing space that has been designed specifically to support the scale of autologous manufacturing. This in-house operation has the capability to produce clinical and future commercial-scale supply of the company's investigational gene therapies, with space available for future expansion.

Working to Bring Major Advances in Care to Patients in Need

The company's lead investigational gene therapy, D-Fi (debcoemagene autoficel, formerly designated FCX-007), is being evaluated in a Phase 3 clinical trial for the localized treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe and debilitating form of EB. The FDA has granted regenerative medicine advanced therapy (RMAT), orphan drug, rare pediatric disease and fast track designations for the development of D-Fi.

The company is also evaluating FCX-013, an investigational gene therapy, in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma, a painful and debilitating chronic autoimmune skin disorder. The FDA has granted orphan drug, rare pediatric disease and fast track designations for FCX-013.

In addition, an investigational, topical diacerein ointment, CCP-020, is under clinical study for the treatment of epidermolysis bullosa simplex (EBS) and potentially other forms of EB. CCP-020 has received fast track, rare pediatric disease and orphan drug designations from the FDA.

Committed to Life Science Innovation

Castle Creek Biosciences is a portfolio company of Paragon Biosciences—a life science innovator that creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals. The company's current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation.

Corporate Contact

Karen Casey
Castle Creek Biosciences, Inc.
(302) 750-4675

Media Contact

Adam Daley
Berry & Company Public Relations
(614) 580-2048

Follow us on Twitter @CastleCreekBio
and LinkedIn at linkedin.com/company/castlecreekbio
and find us on Facebook at facebook.com/castlecreekbio.

Executive Leadership Team

John Maslowski
Chief Executive Officer

Mary Spellman, MD, FAAD
Chief Medical Officer

Gregory MacMichael, PhD
Chief Technology Officer

Greg Wujek
Chief Commerical Officer

Babar Ghias
Chief Operating Officer

Sean Buckley
Chief Business Officer

"We believe our experience, expertise and proven processes provide us with an opportunity to develop and evaluate new personalized therapies that are designed for durability and formulated to be compatible with each patient's unique biology."

— **Dr. Mary Spellman,** ***Chief Medical Officer***

Castle Creek Biosciences, Inc.
405 Eagleview Boulevard
Exton, PA 19341
castlecreekbio.com

UPDATED NOVEMBER-2020